Jpmorgan Chase & CO Bio Line Rx Ltd. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,501 shares of BLRX stock, worth $645. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,501Holding current value
$645% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BLRX
# of Institutions
38Shares Held
4.34MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$839,9470.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$350,7434.05% of portfolio
-
Envestnet Asset Management Inc214KShares$91,9480.0% of portfolio
-
Values First Advisors, Inc.198KShares$84,9310.06% of portfolio
-
Atria Investments LLC Charlotte, NC134KShares$57,6080.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $26.5M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...